1
|
Gil HM, Booth Z, Price TW, Lee J, Naylor-Adamson L, Avery M, Muravitskaya A, Hondow N, Allsup D, Schneider JE, Naseem K, Adawi AM, Bouillard JSG, Chamberlain TW, Calaminus SDJ, Stasiuk GJ. Impact of Surface Ligand on the Biocompatibility of InP/ZnS Quantum Dots with Platelets. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2024; 20:e2304881. [PMID: 37946631 DOI: 10.1002/smll.202304881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 10/24/2023] [Indexed: 11/12/2023]
Abstract
InP/ZnS quantum dots (QDs) have received a large focus in recent years as a safer alternative to heavy metal-based QDs. Given their intrinsic fluorescent imaging capabilities, these QDs can be potentially relevant for in vivo platelet imaging. The InP/ZnS QDs are synthesized and their biocompatibility investigated through the use of different phase transfer agents. Analysis of platelet function indicates that platelet-QD interaction can occur at all concentrations and for all QD permutations tested. However, as the QD concentration increases, platelet aggregation is induced by QDs alone independent of natural platelet agonists. This study helps to define a range of concentrations and coatings (thioglycolic acid and penicillamine) that are biocompatible with platelet function. With this information, the platelet-QD interaction can be identified using multiple methods. Fluorescent lifetime imaging microscopy (FLIM) and confocal studies have shown QDs localize on the surface of the platelet toward the center while showing evidence of energy transfer within the QD population. It is believed that these findings are an important stepping point for the development of fluorescent probes for platelet imaging.
Collapse
Affiliation(s)
- Hélio M Gil
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK
- Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX, UK
| | - Zoe Booth
- Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX, UK
| | - Thomas W Price
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK
| | - Jessica Lee
- Centre for Biomedicine, University of Hull, Hull , HU6 7RX, UK
| | - Leigh Naylor-Adamson
- Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX, UK
| | - Michelle Avery
- Centre for Biomedicine, University of Hull, Hull , HU6 7RX, UK
| | - Alina Muravitskaya
- Department of Physics and Mathematics, University of Hull, Hull , HU6 7RX, UK
| | - Nicole Hondow
- School of Chemical and Process Engineering, University of Leeds, Leeds, LS2 9JT, UK
| | - David Allsup
- Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX, UK
| | | | - Khalid Naseem
- Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, LS2 9JT, UK
| | - Ali M Adawi
- Department of Physics and Mathematics, University of Hull, Hull , HU6 7RX, UK
| | | | - Thomas W Chamberlain
- Institute of Process Research and Development School of Chemistry, University of Leeds, Leeds, LS2 9JT, UK
| | - Simon D J Calaminus
- Centre for Biomedicine, Hull York Medical School, University of Hull, Hull, HU6 7RX, UK
| | - Graeme J Stasiuk
- Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE1 7EH, UK
| |
Collapse
|
2
|
Karkabounas S, Papadopoulos N, Anastasiadou C, Gubili C, Peschos D, Daskalou T, Fikioris N, Simos YV, Kontargiris E, Gianakopoulos X, Ragos V, Chatzidimitriou M. Effects of α-Lipoic Acid, Carnosine, and Thiamine Supplementation in Obese Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind Study. J Med Food 2018; 21:1197-1203. [PMID: 30311825 DOI: 10.1089/jmf.2018.0007] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Type 2 diabetes mellitus (T2DM) is evolving to an epidemic of the modern world. T2DM is associated with a number of pathological complications, including cardiovascular disease that is mostly promoted by the increased oxidative stress in type 2 diabetic patients. We performed a randomized double-blind placebo-controlled trial to investigate the effectiveness of an individualized oral supplementation with α-lipoic acid (ALA), carnosine, and thiamine. For that purpose, 82 obese type 2 diabetic patients were randomly assigned to 2 groups, and were either supplemented daily with 7 mg ALA/kg body weight, 6 mg carnosine/kg body weight, and 1 mg thiamine/kg body weight or placebo for 8 weeks. An array of biochemical tests including the estimation of oxidative stress and platelet aggregation were performed at baseline and at follow-up. Moreover, the antiplatelet activity of each of the supplement's components was determined ex vivo at human and washed rabbit platelets. Glucose and HbA1c levels were significantly reduced after supplementation (135.7 ± 19.5 mg/dL vs. 126.5 ± 16.8 mg/dL and 8.3% ± 0.3% vs. 6.03% ± 0.58%, respectively, P < .05); however, insulin was significantly increased (3.6 ± 0.7 μIU/mL vs. 6.8 ± 0.2 μIU/mL, P < .05). The patients treated with the supplement recorded higher follow-up values for HOMA-IR and HOMA-β, and a significant drop in serum hydroperoxide level. Only ALA inhibited platelets aggregation ex vivo through ADP, platelet activating factor, arachidonic acid, epinephrine, collagen, and thrombin pathways. Daily supplementation with an individualized ALA, carnosine, and thiamine supplement effectively reduced glucose concentration in type 2 diabetic patients, probably by increasing insulin production from the pancreas. In addition to that, the reduction of oxidative stress and inhibition of platelet aggregation could potentially provide greater cardiovascular protection. Further studies are needed to fine-tune the supplementation dose-response effects in T2DM patients.
Collapse
Affiliation(s)
- Spyridon Karkabounas
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece
| | - Nikolaos Papadopoulos
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece
| | - Chryssa Anastasiadou
- 2 Hellenic Agricultural Organization, Fisheries Research Institute , Kavala, Greece
| | - Chrysoula Gubili
- 2 Hellenic Agricultural Organization, Fisheries Research Institute , Kavala, Greece
| | - Dimitrios Peschos
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece
| | | | - Nikolaos Fikioris
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece
| | - Yannis V Simos
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece
| | - Evangelos Kontargiris
- 1 Department of Physiology, Faculty of Medicine, School of Health Sciences; Medical Department; University of Ioannina , Ioannina, Greece .,4 Department of Nursing, Epirus Institute of Technology (T.E.I. of Epirus) , Ioannina, Greece
| | | | - Vasilios Ragos
- 6 Clinic of Maxillofacial Surgery, Medical Department; University of Ioannina , Ioannina, Greece
| | - Maria Chatzidimitriou
- 7 Medical Laboratories, Alexander Technological Institute of Thessaloniki , Thessaloniki, Greece
| |
Collapse
|
3
|
Liu J, Song Q, Huang Y, Sun W, Lu D, Zhou B. R-lipoic acid overdosing affects platelet life span via ROS mediated autophagy. Platelets 2017; 29:695-701. [DOI: 10.1080/09537104.2017.1356450] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Jing Liu
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| | - Qingqing Song
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| | - Yanwei Huang
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| | - Wu Sun
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| | - Dingqiang Lu
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| | - Bo Zhou
- Jiangsu Center for Safety Evaluation of Drugs, Jiangsu Province Institute of Materia Medica, School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing 211800, China
| |
Collapse
|
4
|
Muñoz-Gutiérrez C, Sepúlveda C, Caballero J, Palomo I, Fuentes E. Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. Life Sci 2017; 186:59-65. [PMID: 28757415 DOI: 10.1016/j.lfs.2017.07.031] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Revised: 07/26/2017] [Accepted: 07/27/2017] [Indexed: 12/27/2022]
Abstract
Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor with an important role in lipid metabolism, inflammation and cardiovascular diseases. PPARγ ligands have inhibitory effects on platelet aggregation via the cAMP pathway, which may confer them a protective cardioprotective role. Edaglitazone and Ciglitazone are two chemically-similar thiazolidinedione (TZD) drugs that have been described as potent PPARγ agonists; however, Edaglitazone is over 100 times more potent than Ciglitazone. Here, we report a computational study to describe the ligand binding and the experimental antiplatelet profiles of Edaglitazone and Ciglitazone. Both ligands presented similar orientations within the PPARγ binding site. Their polar heads exhibit complex hydrogen bond networks with the residues at arm I pocket, while their hydrophobic tails are oriented inside arm II or the entrance pocket. The bulkier and longer tail of Edaglitazone exhibited additional hydrophobic interactions, explaining its stronger binding to PPARγ supported by binding affinity calculations. On the other hand, both Edaglitazone and Ciglitazone displayed an antiplatelet activity, but only Edaglitazone retained such effect at low concentrations. Furthermore, we evidenced that Edaglitazone increases intraplatelet cAMP levels and prevents PPARγ secretion, explaining its greater antiplatelet activity. Altogether, the more potent PPARγ agonist Edaglitazone seems to be a potent antiplatelet agent.
Collapse
Affiliation(s)
- Camila Muñoz-Gutiérrez
- Centro de Bioinformática y Simulación Molecular (CBSM), Universidad de Talca, Talca, Chile
| | - Cesar Sepúlveda
- Platelet Research Center, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Universidad de Talca, Talca, Chile
| | - Julio Caballero
- Centro de Bioinformática y Simulación Molecular (CBSM), Universidad de Talca, Talca, Chile.
| | - Iván Palomo
- Platelet Research Center, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Universidad de Talca, Talca, Chile
| | - Eduardo Fuentes
- Platelet Research Center, Department of Clinical Biochemistry and Immunohematology, Faculty of Health Sciences, Interdisciplinary Excellence Research Program on Healthy Aging (PIEI-ES), Universidad de Talca, Talca, Chile; Núcleo Científico Multidisciplinario, Universidad de Talca, Talca, Chile.
| |
Collapse
|
5
|
Rousseau AS, Sibille B, Murdaca J, Mothe-Satney I, Grimaldi PA, Neels JG. α-Lipoic acid up-regulates expression of peroxisome proliferator-activated receptor β in skeletal muscle: involvement of the JNK signaling pathway. FASEB J 2015; 30:1287-99. [PMID: 26655383 DOI: 10.1096/fj.15-280453] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 11/16/2015] [Indexed: 11/11/2022]
Abstract
We hypothesized that α-lipoic acid (α-LA) might interact with the transcriptional control of peroxisome proliferator-activated receptor (PPAR)β in skeletal muscle. Molecular mechanisms were investigated using differentiated C2C12 myotubes treated with α-LA and/or PPARβ agonist GW0742. In vivo studies with 3-mo-old C57Bl6 mice were realized: voluntary wheel running (VWR) training (7 wk), and a 6 wk diet containing (or not) α-LA (0.25% wt/wt). This last condition was combined with (or not) 1 bout of treadmill exercise (18 m/min for 1 h). Using a reporter assay, we demonstrate that α-LA is not an agonist of PPARβ but regulates PPARβ target gene expression through an active PPARβ pathway. GW0742-induced pyruvate dehydrogenase kinase 4 mRNA is potentiated by α-LA. In C2C12, α-LA lowers the activation of the JNK signaling pathway and increases PPARβ mRNA and protein levels (2-fold) to the same extent as with the JNK inhibitor SP600125. Similarly to VWR training effect, PPARβ expression increases (2-fold) in vastus lateralis of animals fed an α-LA-enriched diet. However, α-LA treatment does not further stimulate the adaptive up-regulation of PPARβ observed in response to 1 bout of exercise. We have identified a novel mechanism of regulation of PPARβ expression/action in skeletal muscle with potential physiologic application through the action of α-LA, involving the JNK pathway.
Collapse
Affiliation(s)
- Anne-Sophie Rousseau
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| | - Brigitte Sibille
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| | - Joseph Murdaca
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| | - Isabelle Mothe-Satney
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| | - Paul A Grimaldi
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| | - Jaap G Neels
- Institut National de la Santé et de la Recherche Médicale, Unité 1065, Mediterranean Center of Molecular Medicine (C3M), Nice, France; and University of Nice-Sophia Antipolis, Nice, France
| |
Collapse
|
6
|
Ivanov IS, Sidehmenova AV, Smol'yakova VI, Chernysheva GA, Plotnikov MB. Inhibition of adenosine diphosphate-induced platelet aggregation by alpha-lipoic acid and dihydroquercetin in vitro. Indian J Pharmacol 2015; 46:430-2. [PMID: 25097284 PMCID: PMC4118539 DOI: 10.4103/0253-7613.135958] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2013] [Revised: 11/19/2013] [Accepted: 04/30/2014] [Indexed: 11/26/2022] Open
Abstract
Objectives: To investigate the antiplatelet activity of alpha-lipoic acid (α-LA) and dihydroquercetin (DHQ). Materials and Methods: Antiplatelet activity of the α-LA and DHQ was evaluated in rich platelet plasma of rat. The platelet aggregation was induced by adenosine diphosphate (ADP) in concentration of 4 × 10-5 M. Results: α-LA and DHQ inhibited platelet aggregation in concentration-dependent manner. The antiplatelet activity of α-LA was more pronounced than DHQ. DHQ also increased the antiplatelet activity of α-LA by 1.4 times. Conclusion: Combined simultaneous use of α-LA and DHQ possessed the high antiplatelet activity, and DHQ potentiated the activity of α-LA.
Collapse
Affiliation(s)
- Ivan S Ivanov
- E.D.Goldberg Institute of Pharmacology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia
| | - Anastasia V Sidehmenova
- E.D.Goldberg Institute of Pharmacology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia
| | - Vera I Smol'yakova
- E.D.Goldberg Institute of Pharmacology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia
| | - Galina A Chernysheva
- E.D.Goldberg Institute of Pharmacology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia
| | - Mark B Plotnikov
- E.D.Goldberg Institute of Pharmacology, Siberian Branch, Russian Academy of Medical Sciences, Tomsk, Russia ; Tomsk State University, Tomsk, Russia
| |
Collapse
|
7
|
Lannan KL, Sahler J, Kim N, Spinelli SL, Maggirwar SB, Garraud O, Cognasse F, Blumberg N, Phipps RP. Breaking the mold: transcription factors in the anucleate platelet and platelet-derived microparticles. Front Immunol 2015; 6:48. [PMID: 25762994 PMCID: PMC4327621 DOI: 10.3389/fimmu.2015.00048] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 01/26/2015] [Indexed: 01/15/2023] Open
Abstract
Platelets are small anucleate blood cells derived from megakaryocytes. In addition to their pivotal roles in hemostasis, platelets are the smallest, yet most abundant, immune cells and regulate inflammation, immunity, and disease progression. Although platelets lack DNA, and thus no functional transcriptional activities, they are nonetheless rich sources of RNAs, possess an intact spliceosome, and are thus capable of synthesizing proteins. Previously, it was thought that platelet RNAs and translational machinery were remnants from the megakaryocyte. We now know that the initial description of platelets as "cellular fragments" is an antiquated notion, as mounting evidence suggests otherwise. Therefore, it is reasonable to hypothesize that platelet transcription factors are not vestigial remnants from megakaryocytes, but have important, if only partly understood functions. Proteins play multiple cellular roles to minimize energy expenditure for maximum cellular function; thus, the same can be expected for transcription factors. In fact, numerous transcription factors have non-genomic roles, both in platelets and in nucleated cells. Our lab and others have discovered the presence and non-genomic roles of transcription factors in platelets, such as the nuclear factor kappa β (NFκB) family of proteins and peroxisome proliferator-activated receptor gamma (PPARγ). In addition to numerous roles in regulating platelet activation, functional transcription factors can be transferred to vascular and immune cells through platelet microparticles. This method of transcellular delivery of key immune molecules may be a vital mechanism by which platelet transcription factors regulate inflammation and immunity. At the very least, platelets are an ideal model cell to dissect out the non-genomic roles of transcription factors in nucleated cells. There is abundant evidence to suggest that transcription factors in platelets play key roles in regulating inflammatory and hemostatic functions.
Collapse
Affiliation(s)
- Katie L Lannan
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Julie Sahler
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Biological and Environmental Engineering, Cornell University , Ithaca, NY , USA
| | - Nina Kim
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Sherry L Spinelli
- Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Sanjay B Maggirwar
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Olivier Garraud
- Faculté de Médecine, Université de Lyon , Saint-Etienne , France
| | - Fabrice Cognasse
- Faculté de Médecine, Université de Lyon , Saint-Etienne , France ; Etablissement Français du Sang Auvergne-Loire , Saint-Etienne , France
| | - Neil Blumberg
- Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| | - Richard P Phipps
- Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA ; Department of Environmental Medicine, University of Rochester School of Medicine and Dentistry , Rochester, NY , USA
| |
Collapse
|
8
|
Chou TC. New mechanisms of antiplatelet activity of nifedipine, an L-type calcium channel blocker. Biomedicine (Taipei) 2014; 4:24. [PMID: 25520937 PMCID: PMC4265014 DOI: 10.7603/s40681-014-0024-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2014] [Accepted: 11/05/2014] [Indexed: 01/03/2023] Open
Abstract
Platelet hyperactivity often occursd in hypertensive patients and is a key factor in the development of cardiovascular diseases including thrombosis and atherosclerosis. Nifedipine, an L-type calcium channel blocker, is widely used for hypertension and coronary heart disease therapy. In addition, nifedipine is known to exhibit an antiplatelet activity, but the underlying mechanisms involved remain unclear. Several transcription factors such as peroxisome proliferator-activated receptors (PPARs) and nuclear factor kappa B (NF-κB) exist in platelets and have an ability to regulate platelet aggregation through a non-genomic mechanism. The present article focuses on describing the mechanisms of the antiplatelet activity of nifedipine via PPAR activation. It has been demonstrated that nifedipine treatment increases the activity and intracellular amount of PPAR-β/-γ in activated platelets. Moreover, the antiplatelet activity of nifedipine is mediated by PPAR-β/-γ-dependent upon the up-regulation of the PI3K/AKT/NO/cyclic GMP/PKG pathway, and inhibition of protein kinase Cα (PKCα) activity via an interaction between PPAR-β/-γ and PKCα. Furthermore, suppressing NF-κB activation by nifedipine through enhanced association of PPAR-β/-γ with NF-κB has also been observed in collagen-stimulated platelets. Blocking PPAR-β/-γ activity or increasing NF-κB activation greatly reverses the antiplatelet activity and inhibition of intracellular Ca2+ mobilization, PKCα activity, and surface glycoprotein IIb/IIIa expression caused by nifedipine. Thus, PPAR-β/-γ- dependent suppression of NF-κB activation also contributes to the antiplatelet activity of nifedipine. Consistently, administration of nifedipine markedly reduces fluorescein sodium-induced vessel thrombus formation in mice, which is considerably inhibited when the PPAR-β/-γ antagonists are administrated simultaneously. Collectively, these results provide important information regarding the mechanism by which nifedipine inhibits platelet aggregation and thrombus formation through activation of PPAR-β/-γ- mediated signaling pathways. These findings highlight that PPARs are novel therapeutic targets for preventing and treating platelet-hyperactivity-related vascular diseases.
Collapse
Affiliation(s)
- Tz-Chong Chou
- Institute of Medical Sciences, Tzu Chi University, 6F, Xie-Li Building, No. 707, Sec. 3, Zhongyang Rd.,, 970 Hualien, Taiwan
| |
Collapse
|
9
|
Shih CY, Lin IH, Ding JC, Chen FC, Chou TC. Antiplatelet activity of nifedipine is mediated by inhibition of NF-κB activation caused by enhancement of PPAR-β/-γ activity. Br J Pharmacol 2014; 171:1490-1500. [PMID: 24730061 DOI: 10.1111/bph.12523] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND AND PURPOSE The transcription factor NF-κB, stimulates platelet aggregation through a non-genomic mechanism. Nifedipine, a voltage-gated L-type calcium channel blocker, is widely used to treat hypertension. Nifedipine also displays antiplatelet activity, but the underlying mechanisms involved remain unclear. This study was designed to investigate whether the antiplatelet effects of nifedipine are mediated by regulating NF-κB-dependent responses. EXPERIMENTAL APPROACH Platelet aggregation was measured turbidimetrically using an aggregometer. NF-κB and PPAR activation, intracellular Ca2+ mobilization, PKCα activity, surface glycoprotein IIb/IIIa (GPIIb/IIIa) expression and platelet activation-related signalling pathways were determined in control and nifedipine-treated platelets in the presence or absence of PPAR antagonists or betulinic acid, a NF-κB activator. KEY RESULTS Exposure of platelets to nifedipine significantly increased the PPAR-β/-γ activity in activated human platelets. Treatment with nifedipine reduced collagen-induced NF-κB events, including the phosphorylation of IκB kinase-β, IκBα and p65NF-κB, which were markedly attenuated by GSK0660, a PPAR-β antagonist, or GW9662, a PPAR-γ antagonist. Furthermore, the interaction of PPAR-β/-γ with NF-κB and the PPAR-β/-γ-up-regulated NO/cGMP/PKG1 cascade may contribute to inhibition of NF-κB activation by nifedipine. Suppressing PPAR-β/-γ activity or increasing NF-κB activation greatly reversed the inhibitory effect of nifedipine on collagen-induced platelet aggregation, intracellular Ca2+ mobilization, PKCα activity and surface GPIIb/IIIa expression.CONCLUSIONS AND IMPLICATIONSPPAR-β/-γ-dependent inhibition of NF-κB activation contributes to the antiplatelet activity of nifedipine. These findings provide a novel mechanism underlying the beneficial effects of nifedipine on platelet hyperactivity-related vascular and inflammatory diseases.
Collapse
|
10
|
Du H, Hu H, Zheng H, Hao J, Yang J, Cui W. Effects of peroxisome proliferator-activated receptor γ in simvastatin antiplatelet activity: influences on cAMP and mitogen-activated protein kinases. Thromb Res 2014; 134:111-20. [PMID: 24856644 DOI: 10.1016/j.thromres.2014.05.005] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 04/25/2014] [Accepted: 05/05/2014] [Indexed: 12/14/2022]
Abstract
Statins are widely used as hypolipidemic drugs, and have beneficial effects in reducing cardiovascular events. In addition, recent studies on the pleiotropic effects of statins (i.e., simvastatin) reveal that these drugs have many additional anti-atherogenic effects, including antiplatelet activity. The mechanisms may be partly related to activation of peroxisome proliferator-activated receptors (PPARs), which are present in human platelets, and whose activation inhibits platelet aggregation. However, the details of the signaling pathway by which simvastatin inhibits platelet activation via PPARs have not yet been completely established. The aim of this study was to examine the mechanisms by which the PPAR-mediated pathways contribute to the antiplatelet activity of simvastatin. Simvastatin (3-50 μM) induced PPARα and PPARγ activation in a dose-dependent manner in washed platelets. Additionally, simvastatin inhibited collagen-induced platelet aggregation, expression of CD62 and PAC-1, and Ca(2+) mobilization. These effects of simvastatin on platelet responses were strongly reduced by adding a selective PPARγ antagonist (GW9662), but not PPARα antagonist (GW6471). Moreover, in the presence of GW9662, simvastatin-mediated increase of cyclic adenosine monophosphate (cAMP) production, vasodilator-stimulated phosphoprotein (VASP) Ser(157) phosphorylation and inhibition of Akt phosphorylation were markedly reversed. Furthermore, simvastatin was found to inhibit phosphorylation of mitogen-activated protein kinases (MAPKs, i.e., p38 MAPK, ERK) by increasing the association between PPARγ and the components of MAPKs after platelet activation. Taken together, the present results confirm that simvastatin inhibition of platelet activation is mediated by PPARγ-dependent processes, which involves mediating MAPKs signaling, increase of cAMP formation and VASP Ser(157) phosphorylation, inhibition of Akt phosphorylation and intracellular Ca(2+) mobilization.
Collapse
Affiliation(s)
- Hong Du
- Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei
| | - Haijuan Hu
- Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei
| | - Hongmei Zheng
- Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei
| | - Jie Hao
- Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei
| | - Jingci Yang
- Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei
| | - Wei Cui
- Department of Cardiology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei.
| |
Collapse
|
11
|
Antiplatelet effects of natural bioactive compounds by multiple targets: Food and drug interactions. J Funct Foods 2014. [DOI: 10.1016/j.jff.2013.10.012] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
|
12
|
|
13
|
Mauritia flexuosa Presents In Vitro and In Vivo Antiplatelet and Antithrombotic Activities. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:653257. [PMID: 24454503 PMCID: PMC3878763 DOI: 10.1155/2013/653257] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/30/2013] [Revised: 11/04/2013] [Accepted: 11/04/2013] [Indexed: 12/28/2022]
Abstract
Fruit from the palm Mauritia flexuosa is one of the most important species in Peru, Venezuela, Brazil, Colombia, Bolivia, and Guyana. The present study aimed to investigate the antiplatelet and antithrombotic activities of oil extracted from Mauritia flexuosa. The fatty acid contents were determined by gas chromatography—mass spectrometry. Oil extract of peel of Mauritia flexuosa was extracted by soxhlet extraction. The oil extract inhibited platelet secretion and aggregation induced by ADP, collagen, and TRAP-6 by a concentration-dependent way (0.1 to 1 mg/mL) without the participation of the adenylyl cyclase pathway and diminished platelet rolling and firm adhesion under flow conditions. Furthermore, the oil extract induced a marked increase in the rolling speed of leukocytes retained on the platelet surface, reflecting a reduction of rolling and less adhesion. At the concentrations used, the oil extract significantly decreased platelet release of sP-selectin, an atherosclerotic-related inflammatory mediator. Oil extract inhibited thrombus growth at the same concentration as that of aspirin, a classical reference drug. Finally, the data presented herein also demonstrate for the first time to our knowledge the protective effect of oil extracted from Mauritia flexuosa on platelet activation and thrombosis formation.
Collapse
|
14
|
Fuentes E, Fuentes F, Palomo I. Mechanism of the anti-platelet effect of natural bioactive compounds: Role of peroxisome proliferator-activated receptors activation. Platelets 2013; 25:471-9. [DOI: 10.3109/09537104.2013.849334] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
15
|
Relationship between Platelet PPARs, cAMP Levels, and P-Selectin Expression: Antiplatelet Activity of Natural Products. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2013; 2013:861786. [PMID: 24324520 PMCID: PMC3845334 DOI: 10.1155/2013/861786] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/14/2013] [Accepted: 09/23/2013] [Indexed: 11/22/2022]
Abstract
Platelets are no longer considered simply as cells participating in thrombosis. In atherosclerosis, platelets are regulators of multiple processes, with the recruitment of inflammatory cells towards the lesion sites, inflammatory mediators release, and regulation of endothelial function. The antiplatelet therapy has been used for a long time in an effort to prevent and treat cardiovascular diseases. However, limited efficacy in some patients, drug resistance, and side effects are limitations of current antiplatelet therapy. In this context, a large number of natural products (polyphenols, terpenoids, alkaloids, and fatty acids) have been reported with antiplatelet activity. In this sense, the present paper describes mechanisms of antiplatelet action of natural products on platelet P-selectin expression through cAMP levels and its role as peroxisome proliferator-activated receptors agonists.
Collapse
|
16
|
α-Lipoic acid enhances endogenous peroxisome-proliferator-activated receptor-γ to ameliorate experimental autoimmune encephalomyelitis in mice. Clin Sci (Lond) 2013; 125:329-40. [PMID: 23550596 DOI: 10.1042/cs20120560] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
ALA (α-lipoic acid) is a natural, endogenous antioxidant that acts as a PPAR-γ (peroxisome-proliferator-activated receptor-γ) agonist to counteract oxidative stress. Thus far, the antioxidative and immunomodulatory effects of ALA on EAE (experimental autoimmune encephalomyelitis) are not well understood. In this study, we found that ALA restricts the infiltration of inflammatory cells into the CNS (central nervous system) in MOG (myelin oligodendrocyte glycoprotein)-EAE mice, thus reducing the disease severity. In addition, we revealed that ALA significantly suppresses the number and percentage of encephalitogenic Th1 and Th17 cells and increases splenic Treg-cells (regulatory T-cells). Strikingly, we further demonstrated that ALA induces endogenous PPAR-γ centrally and peripherally but has no effect on HO-1 (haem oxygenase 1). Together, these data suggest that ALA can up-regulate endogenous systemic and central PPAR-γ and enhance systemic Treg-cells to inhibit the inflammatory response and ameliorate MOG-EAE. In conclusion, our data provide the first evidence that ALA can augment the production of PPAR-γ in vivo and modulate adaptive immunity both centrally and peripherally in EAE and may reveal further antioxidative and immunomodulatory mechanisms for the application of ALA in human MS (multiple sclerosis).
Collapse
|
17
|
Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm 2013; 2013:549627. [PMID: 23781121 PMCID: PMC3678499 DOI: 10.1155/2013/549627] [Citation(s) in RCA: 238] [Impact Index Per Article: 21.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2012] [Revised: 04/03/2013] [Accepted: 04/17/2013] [Indexed: 12/13/2022] Open
Abstract
Metabolic syndrome is estimated to affect more than one in five adults, and its prevalence is growing in the adult and pediatric populations. The most widely recognized metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a proinflammatory state as well. Peroxisome proliferator-activated receptors (PPARs) may serve as potential therapeutic targets for treating the metabolic syndrome and its related risk factors. The PPARs are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. So far, three isoforms of PPARs have been identified, namely, PPAR- α, PPAR-β/δ, and PPAR-γ. Various endogenous and exogenous ligands of PPARs have been identified. PPAR- α and PPAR- γ are mainly involved in regulating lipid metabolism, insulin sensitivity, and glucose homeostasis, and their agonists are used in the treatment of hyperlipidemia and T2DM. Whereas PPAR- β / δ function is to regulate lipid metabolism, glucose homeostasis, anti-inflammation, and fatty acid oxidation and its agonists are used in the treatment of metabolic syndrome and cardiovascular diseases. This review mainly focuses on the biological role of PPARs in gene regulation and metabolic diseases, with particular focus on the therapeutic potential of PPAR modulators in the treatment of thrombosis.
Collapse
Affiliation(s)
- Francisco A. Monsalve
- Departamento Ciencias Biomédicas, Facultad Ciencias de la Salud, Universidad de Talca, Chile
- Instituto de Químicas y Recursos Naturales, Universidad de Talca, Chile
| | | | | | - Rodrigo Moore-Carrasco
- Departamento de Bioquímica Clínica e Inmunohematología, Facultad Ciencias de la Salud, Universidad de Talca, Chile
| |
Collapse
|
18
|
The antiplatelet activity of magnolol is mediated by PPAR-β/γ. Biochem Pharmacol 2012; 84:793-803. [PMID: 22750553 DOI: 10.1016/j.bcp.2012.06.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2012] [Revised: 06/13/2012] [Accepted: 06/21/2012] [Indexed: 11/20/2022]
Abstract
Activation of peroxisome proliferator-activated receptor (PPAR) isoforms (α, β/δ, and γ) is known to inhibit platelet aggregation. In the present study, we examined whether PPARs-mediated pathways contribute to the antiplatelet activity of magnolol, a compound purified from Magnolia officinalis. Magnolol (20-60 μM) dose-dependently enhanced the activity and intracellular level of PPAR-β/γ in platelets. In the presence of selective PPAR-β antagonist (GSK0660) or PPAR-γ antagonist (GW9662), the inhibition of magnolol on collagen-induced platelet aggregation and intracellular Ca(2+) mobilization was significantly reversed. Moreover, magnolol-mediated up-regulation of NO/cyclic GMP/PKG pathway and Akt phosphorylation leading to increase of eNOS activity were markedly abolished by blocking PPAR-β/γ activity. Additionally, magnolol significantly inhibited collagen-induced PKCα activation through a PPAR-β/γ and PKCα interaction manner. The arachidonic acid (AA) or collagen-induced thromboxane B(2) formation and elevation of COX-1 activity caused by AA were also markedly attenuated by magnolol. However, these above effects of magnolol on platelet responses were strongly reduced by simultaneous addition of GSK0660 or GW9662, suggesting that PPAR-β/γ-mediated processes may account for magnolol-regulated antiplatelet mechanisms. Similarly, administration of PPAR-β/γ antagonists remarkably abolished the actions of magnolol in preventing platelet plug formation and prolonging bleeding time in mice. Taken together, we demonstrate for the first time that the antiplatelet and anti-thrombotic activities of magnolol are modulated by up-regulation of PPAR-β/γ-dependent pathways.
Collapse
|
19
|
Current World Literature. Curr Opin Nephrol Hypertens 2012; 21:106-18. [DOI: 10.1097/mnh.0b013e32834ee42b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Choi Y. Evolving Coronary Stents Coated With New Bioactive Agents. Korean Circ J 2011; 41:233-4. [PMID: 21731562 PMCID: PMC3116099 DOI: 10.4070/kcj.2011.41.5.233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Yunseok Choi
- Division of Cardiology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
| |
Collapse
|